目的 观察卡培他滨(capecitabine,CAP)联合贝伐珠单抗(bevacizumab,BEV)治疗表皮生长因子2(HER2)阴性局部复发/转移性乳腺癌(locally recurrent/metastatic breast cancer,LR/mBC)时,手足综合征(hand-foot syndrome,HFS)的出现与患者治疗疗效的相关性.方法 给予来自陕西中医药大学附属医院门诊或住院收治的100例HER2阴性LR/mBC患者行CAP-BEV一线全身化疗,根据患者是否出现HFS将其分为HFS组和非HFS组,利用Kaplan-Meier方法绘制PFS和OS生存曲线.结果 HFS组患者的PFS为10.7个月,而非HFS组仅5.8个月,经Log-rank检验,两组PFS生存曲线差别具有统计学意义(x2=23.63,P=0.000);HFS组因OS最小生存率＞0.50,未得出具体数值,而非HFS组的OS为14.9个月,其生存曲线具有显著统计学意义(x2=34.04,P=0.000).针对不同程度HFS进行进一步分析,可见Ⅱ级HFS患者的PFS和OS生存曲线最高.结论 CAP-BEV治疗HER2阴性LR/mBC患者时,如果患者出现HFS,尤其是Ⅱ级HFS时,其预后将显著优于未出现HFS患者.%Objective To observe the correlation between HFS and therapeutic effect that CAP plus BEV in treatment of HER2-negative LR/mBC.Methods 100 HER2-negative LR/mBC patients from The Affiliated Hospital of Shanxi University of Traditional Chinese Medicine receiving first-line CAP plus BEV were divided into HFS group and non HFS group according to whether patients with HFS.The survival curves of PFS and OS were plotted by Meier-Kaplan method.Results Median PFS of HFS group and non HFS group were 10.7 months and 5.8 months,which was statistically significantly different (x2=23.63,P=0.000).The HFS group did not reach a specific value because the OS minimum survival rate more than 0.50,and median OS from non HFS group was 14.90 months,which was statistically significantly different (x2 =34.04,P=0.000).The different degree of HFS,PFS and OS survival curves were the highest in patients with grade Ⅱ HFS.Conclusion If the patient appears HFS,especially when the grade Ⅱ HFS,the prog nosis of CAP-BEV treatment of patients with Her2-negative LR/mBC,will be significantly better than that of the patients without HFS.
展开▼
